![With 20 Agents, 803 Trials, and 166,736 Patient Slots, Is Pharma Investing Too Heavily in PD-1 Drug Development?](https://cdn.cancerletter.com/media/2016/10/pd1-TAXI-small-web.jpg)
![With 20 Agents, 803 Trials, and 166,736 Patient Slots, Is Pharma Investing Too Heavily in PD-1 Drug Development?](https://cdn.cancerletter.com/media/2016/10/pd1-TAXI-small-web.jpg)
Cover Story
Free
By Laura Brawley
Pharmaceutical companies are betting big on cancer immunotherapies that rely on the PD-1 protein and its ligands, PD-L1 and PD-L2, to initiate an immune response.
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- Jonathan Gerber named chief clinical officer of NYU Langone Health’s Perlmutter Cancer Center
- Tweaking the existing systems is not the answer to drug shortages